|24.51||+0.7700||+3.24%||Vol 1.78M||1Y Perf 3.84%|
|Apr 20th, 2021 16:00 DELAYED|
|- -||-0.13 -0.53%|
|Target Price||31.33||Analyst Rating||Moderate Buy 1.58|
|Potential %||27.83||Finscreener Ranking||★★★★★ 60.92|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 54.34|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 78.16|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||7.67B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||65.80||Earnings Date||4th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2021|
|Estimated EPS Next Report||0.04|
|EPS Growth Next 5 Years %||47.40|
|Avg. Weekly Volume||1.42M|
|Avg. Monthly Volume||1.60M|
|Avg. Quarterly Volume||1.92M|
Exelixis Inc. (NASDAQ: EXEL) stock closed at 24.51 per share at the end of the most recent trading day (a 3.24% change compared to the prior day closing price) with a volume of 1.79M shares and market capitalization of 7.67B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 773 people. Exelixis Inc. CEO is Michael M. Morrissey.
The one-year performance of Exelixis Inc. stock is 3.84%, while year-to-date (YTD) performance is 22.12%. EXEL stock has a five-year performance of 442.26%. Its 52-week range is between 18.18 and 27.8, which gives EXEL stock a 52-week price range ratio of 65.80%
Exelixis Inc. currently has a PE ratio of 67.40, a price-to-book (PB) ratio of 3.93, a price-to-sale (PS) ratio of 9.77, a price to cashflow ratio of 35.90, a PEG ratio of 2.32, a ROA of 5.34%, a ROC of 7.52% and a ROE of 6.02%. The company’s profit margin is 7.87%, its EBITDA margin is 12.10%, and its revenue ttm is $760.62 Million , which makes it $2.43 revenue per share.
Of the last four earnings reports from Exelixis Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.04 for the next earnings report. Exelixis Inc.’s next earnings report date is 04th May 2021.
The consensus rating of Wall Street analysts for Exelixis Inc. is Moderate Buy (1.58), with a target price of $31.33, which is +27.83% compared to the current price. The earnings rating for Exelixis Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Exelixis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Exelixis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.37, ATR14 : 0.92, CCI20 : 87.93, Chaikin Money Flow : -0.06, MACD : 0.37, Money Flow Index : 72.35, ROC : 5.09, RSI : 54.70, STOCH (14,3) : 66.86, STOCH RSI : 0.60, UO : 48.26, Williams %R : -33.14), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Exelixis Inc. in the last 12-months were: Alan M. Garber (Option Excercise at a value of $135 200), Alan M. Garber (Sold 112 222 shares of value $2 707 661 ), Carl B. Feldbaum (Option Excercise at a value of $337 195), Carl B. Feldbaum (Sold 83 092 shares of value $2 017 762 ), Charles Cohen (Option Excercise at a value of $806 805), Charles Cohen (Sold 40 000 shares of value $907 600 ), Christopher J. Senner (Option Excercise at a value of $585 600), Christopher J. Senner (Sold 160 000 shares of value $4 080 786 ), George A. Scangos (Option Excercise at a value of $527 225), George A. Scangos (Sold 400 000 shares of value $10 379 354 ), George H. Poste (Option Excercise at a value of $829 666), George H. Poste (Sold 60 000 shares of value $1 536 600 ), Gisela M. Schwab (Option Excercise at a value of $510 000), Gisela M. Schwab (Sold 300 000 shares of value $7 138 500 ), Jack L. Wyszomierski (Option Excercise at a value of $363 185), Jack L. Wyszomierski (Sold 34 000 shares of value $700 740 ), Jeffrey J. Hessekiel (Option Excercise at a value of $2 495 626), Jeffrey J. Hessekiel (Sold 163 006 shares of value $4 111 563 ), Lance Willsey (Option Excercise at a value of $1 205 346), Lance Willsey (Sold 180 000 shares of value $4 305 536 ), Michael M. Morrissey (Option Excercise at a value of $6 664 183), Patrick J. Haley (Option Excercise at a value of $119 478), Patrick J. Haley (Sold 111 883 shares of value $2 696 090 ), Peter Lamb (Option Excercise at a value of $860 760), Peter Lamb (Sold 310 000 shares of value $6 770 800 ), Stelios Papadopoulos (Option Excercise at a value of $929 204), Stelios Papadopoulos (Sold 45 000 shares of value $1 162 800 ), Vincent T. Marchesi (Option Excercise at a value of $973 223), Vincent T. Marchesi (Sold 204 101 shares of value $4 826 396 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.